Boehringer Ingelheim's Afatinib Effective for Both Asian, Non-Asian Patients With EGFR-Mutated NSCLC

NEW YORK – Ridgefield, Connecticut-based Boehringer Ingelheim on Tuesday announced pooled data from a collection of randomized clinical trials and real-world studies demonstrating that its TKI afatinib (Gilotrif) is efficacious across EGFR-mutated non-small cell lung cancer patients, regardless of their ethnicity.